Do analysts rate BIOL or GCTK?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. GlucoTrack's return on equity of -581.98% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% GlucoTrack N/A -581.98% -220.10%

Do analysts prefer IVF or BIOL?

INVO Fertility presently has a consensus price target of $20.00, indicating a potential upside of 1,823.08%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities research analysts plainly believe INVO Fertility is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, IVF or BIOL?

BIOLASE has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INVO Fertility $6.84M 0.35 -$25.13M -$352.18 N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Is IVF or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to INVO Fertility's net margin of -183.75%. INVO Fertility's return on equity of -420.62% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets INVO Fertility -183.75% -420.62% -45.21% BIOLASE -41.65% -1,782.73% -55.31%

Do analysts recommend BIOL or TNON?

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Tenon Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenon Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BIOL or TNON more profitable?

BIOLASE has a net margin of -41.65% compared to Tenon Medical's net margin of -270.09%. Tenon Medical's return on equity of -907.60% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Tenon Medical -270.09% -907.60% -110.17%

Do analysts prefer FEED or BIOL?

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is FEED or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -923.20% -54.25% -43.10% BIOLASE -41.65% -1,782.73% -55.31%

Do analysts recommend BIOL or BBLG?

Given BIOLASE's higher possible upside, equities analysts clearly believe BIOLASE is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or BBLG more profitable?

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -50.47% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Bone Biologics N/A -50.47% -47.40%

BIOLASE (BIOL) Competitors

Compare

BIOL vs. GCTK, IVF, TNON, FEED, and BBLG

Should you buy BIOLASE stock or one of its competitors? BIOLASE's main competitors and comparable companies include GlucoTrack (GCTK), INVO Fertility (IVF), Tenon Medical (TNON), Nanovibronix (FEED), and Bone Biologics (BBLG). Companies are selected based on similarities in market, industry, and size.

How does BIOLASE compare to GlucoTrack?

BIOLASE (NASDAQ:BIOL) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

GlucoTrack has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. GlucoTrack's return on equity of -581.98% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
GlucoTrack	N/A	-581.98%	-220.10%

BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 8.4% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GlucoTrack has lower revenue, but higher earnings than BIOLASE. GlucoTrack is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

In the previous week, GlucoTrack had 4 more articles in the media than BIOLASE. MarketBeat recorded 4 mentions for GlucoTrack and 0 mentions for BIOLASE. GlucoTrack's average media sentiment score of 0.10 beat BIOLASE's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
BIOLASE	Neutral
GlucoTrack	Neutral

Summary

GlucoTrack beats BIOLASE on 9 of the 14 factors compared between the two stocks.

How does BIOLASE compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

INVO Fertility presently has a consensus price target of $20.00, indicating a potential upside of 1,823.08%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities research analysts plainly believe INVO Fertility is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.0% of INVO Fertility shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BIOLASE has a net margin of -41.65% compared to INVO Fertility's net margin of -183.75%. INVO Fertility's return on equity of -420.62% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-183.75%	-420.62%	-45.21%
BIOLASE	-41.65%	-1,782.73%	-55.31%

INVO Fertility has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

BIOLASE has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.84M	0.35	-$25.13M	-$352.18	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

In the previous week, INVO Fertility's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
INVO Fertility	Neutral
BIOLASE	Neutral

Summary

INVO Fertility beats BIOLASE on 8 of the 13 factors compared between the two stocks.

How does BIOLASE compare to Tenon Medical?

BIOLASE (NASDAQ:BIOL) and Tenon Medical (NASDAQ:TNON) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

BIOLASE has a net margin of -41.65% compared to Tenon Medical's net margin of -270.09%. Tenon Medical's return on equity of -907.60% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Tenon Medical	-270.09%	-907.60%	-110.17%

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Tenon Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tenon Medical has lower revenue, but higher earnings than BIOLASE. Tenon Medical is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Tenon Medical	$3.94M	18.20	-$12.56M	-$1.29	N/A

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, Tenon Medical had 8 more articles in the media than BIOLASE. MarketBeat recorded 8 mentions for Tenon Medical and 0 mentions for BIOLASE. BIOLASE's average media sentiment score of 0.00 beat Tenon Medical's score of -0.67 indicating that BIOLASE is being referred to more favorably in the media.

Company	Overall Sentiment
BIOLASE	Neutral
Tenon Medical	Negative

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 22.7% of Tenon Medical shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 17.7% of Tenon Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tenon Medical beats BIOLASE on 9 of the 15 factors compared between the two stocks.

How does BIOLASE compare to Nanovibronix?

Nanovibronix (NASDAQ:FEED) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, Nanovibronix had 2 more articles in the media than BIOLASE. MarketBeat recorded 2 mentions for Nanovibronix and 0 mentions for BIOLASE. Nanovibronix's average media sentiment score of 0.66 beat BIOLASE's score of 0.00 indicating that Nanovibronix is being referred to more favorably in the media.

Company	Overall Sentiment
Nanovibronix	Positive
BIOLASE	Neutral

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nanovibronix has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BIOLASE has a net margin of -41.65% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Nanovibronix has higher earnings, but lower revenue than BIOLASE. Nanovibronix is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	0.99	-$18.18M	-$8.82	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Summary

Nanovibronix beats BIOLASE on 10 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Bone Biologics?

BIOLASE (NASDAQ:BIOL) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -50.47% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Bone Biologics	N/A	-50.47%	-47.40%

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 5.6% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bone Biologics has lower revenue, but higher earnings than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Given BIOLASE's higher possible upside, equities analysts clearly believe BIOLASE is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bone Biologics had 1 more articles in the media than BIOLASE. MarketBeat recorded 1 mentions for Bone Biologics and 0 mentions for BIOLASE. BIOLASE's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Bone Biologics	Neutral

Summary

Bone Biologics beats BIOLASE on 10 of the 13 factors compared between the two stocks.

Get BIOLASE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOL vs. The Competition

Export

Metric	BIOLASE	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$581K	$5.82B	$7.02B	$12.98B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	0.00	24.71	269.19	24.71
Price / Sales	N/A	61.03	588.76	97.69
Price / Cash	N/A	33.55	28.89	37.42
Price / Book	N/A	6.21	11.27	6.42
Net Income	-$20.63M	$147.87M	$3.45B	$347.03M

BIOLASE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
GCTK GlucoTrack	0.5376 of 5 stars	$0.29 -5.0%	N/A	-92.6%	$2.32M	N/A	N/A	5	Analyst Upgrade
IVF INVO Fertility	2.4275 of 5 stars	$0.91 -7.0%	$20.00 +2,095.4%	-98.5%	$2.25M	$6.84M	N/A	10
TNON Tenon Medical	1.0149 of 5 stars	$0.19 +1.5%	N/A	-90.6%	$2.25M	$3.94M	N/A	8	Upcoming Earnings Trading Halted
FEED Nanovibronix	0.9537 of 5 stars	$0.33 -3.7%	N/A	N/A	$2.09M	$2.55M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BIOLASE (BIOL) Competitors

BIOL vs. GCTK, IVF, TNON, FEED, and BBLG

How does BIOLASE compare to GlucoTrack?

Summary

How does BIOLASE compare to INVO Fertility?

Summary

How does BIOLASE compare to Tenon Medical?

Summary

How does BIOLASE compare to Nanovibronix?

Summary

How does BIOLASE compare to Bone Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BIOLASE (BIOL) Competitors

BIOL vs. GCTK, IVF, TNON, FEED, and BBLG

How does BIOLASE compare to GlucoTrack?

Is BIOL or GCTK more profitable?

Which has more risk & volatility, BIOL or GCTK?

Do analysts rate BIOL or GCTK?

Do institutionals and insiders have more ownership in BIOL or GCTK?

Which has higher valuation and earnings, BIOL or GCTK?

Does the media refer more to BIOL or GCTK?

Summary

How does BIOLASE compare to INVO Fertility?

Do analysts prefer IVF or BIOL?

Do insiders and institutionals have more ownership in IVF or BIOL?

Is IVF or BIOL more profitable?

Which has more volatility and risk, IVF or BIOL?

Which has stronger valuation and earnings, IVF or BIOL?

Does the media prefer IVF or BIOL?

Summary

How does BIOLASE compare to Tenon Medical?

Is BIOL or TNON more profitable?

Do analysts recommend BIOL or TNON?

Which has higher earnings and valuation, BIOL or TNON?

Which has more risk and volatility, BIOL or TNON?

Does the media favor BIOL or TNON?

Do insiders & institutionals have more ownership in BIOL or TNON?

Summary

How does BIOLASE compare to Nanovibronix?

Does the media prefer FEED or BIOL?

Do analysts prefer FEED or BIOL?

Which has more risk and volatility, FEED or BIOL?

Do institutionals and insiders have more ownership in FEED or BIOL?

Is FEED or BIOL more profitable?

Which has higher valuation & earnings, FEED or BIOL?

Summary

How does BIOLASE compare to Bone Biologics?

Is BIOL or BBLG more profitable?

Do institutionals & insiders hold more shares of BIOL or BBLG?

Which has stronger valuation & earnings, BIOL or BBLG?

Which has more volatility & risk, BIOL or BBLG?

Do analysts recommend BIOL or BBLG?

Does the media favor BIOL or BBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools